The SnoB study: Frequency of baseline raltegravir resistance mutations prevalence in diVerent non-B subtypes

Medical Microbiology and Immunology

Volumn 200, Issue 4, 2011, Pages 225-232

  Sierra, Saleta ^a   Lübke, Nadine ^a   Walter, Hauke ^b   Schülter, Eugen ^a   Reuter, Stefan ^c   Fätkenheuer, Gerd ^a   Bickel, Markus ^d   Da Silva, Hugo ^e   Kaiser, Rolf ^a   Esser, Stefan ^f  

^a UNIVERSITY OF COLOGNE   (Germany)

^b UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^c HEINRICH HEINE UNIVERSITY   (Germany)

^d UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^e MERCK RESEARCH LABORATORIES   (United States)

^f UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

Integrase inhibitors; Non B subtypes; Phenotypic analysis; Polymorphisms; Raltegravir; Resistance mutations

Indexed keywords

RALTEGRAVIR; VIRUS RNA;

ADULT; AGED; ANTIVIRAL RESISTANCE; ARTICLE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DRUG EFFICACY; DRUG TREATMENT FAILURE; FEMALE; GENE MUTATION; GENE SEQUENCE; GENETIC SCREENING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INTEGRASE GENE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MUTATIONAL ANALYSIS; PHENOTYPIC VARIATION; PRIORITY JOURNAL; TREATMENT DURATION; VIRUS GENE; VIRUS MUTATION; VIRUS STRAIN; VIRUS TYPING;

ADOLESCENT; ADULT; AGED; CELL LINE, TUMOR; CHILD; CHILD, PRESCHOOL; DNA MUTATIONAL ANALYSIS; DRUG RESISTANCE, VIRAL; FEMALE; HIV INFECTIONS; HIV INTEGRASE; HIV INTEGRASE INHIBITORS; HIV-1; HUMANS; INFANT; INFANT, NEWBORN; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MUTATION; PHENOTYPE; POLYMORPHISM, GENETIC; PREVALENCE; PROSPECTIVE STUDIES; PYRROLIDINONES; RNA, VIRAL; YOUNG ADULT;

EID: 83055179796     PISSN: 03008584     EISSN: 14321831     Source Type: Journal    
DOI: 10.1007/s00430-011-0194-1     Document Type: Article

References (33)

1. Markowitz M, Morales-Ramirez JO, Nguyen BY, Kovacs CM, Steigbigel RT, Cooper DA, Liporace R, Schwartz R, Isaacs R, Gilde LR, Wenning L, Zhao J, Teppler H (2006) Antiretroviral activity, pharmacokinetics, and tolerability of MK-0518, a novel inhibitor of HIV-1 integrase, dosed as monotherapy for 10 days in treatment-naive HIV-1-infected individuals. J Acquir Immune DeWc Syndr 43(5):509-515
2. Grinsztejn B, Nguyen BY, Katlama C, Gatell J, Lazzarin A, Vittecoq D, Gonzalez C, Chen J, Isaacs R, Team Tps (2006) Potent antiretroviral eVect of MK-0518, a novel HIV-1 integrase inhibitor, in patients with triple-class resistant virus. In: 13th conference on retroviruses and opportunistic infections (CROI), Denver, USA, 5-8 February 2006. p Abstract 159L.B.
3. Cooper D, Gatell J, Rockstroh J, Katlama C, Yeni P, Lazzarin A, Chen J, Isaacs R, Teppler H, Nguyen B, Group B-S (2007) Results of BENCHMRK-1, a phase III study evaluating the eYcacy and safety of MK-0518, a novel HIV-1 integrase inhibitor, in patients with triple-class resistant virus. In: 14th conference on retroviruses and opportunistic infections (CROI), Los Angeles, CA, USA, 25- 28 February 2007. p Abstract 105aL.B.
4. Steigbigel R, Kumar P, Eron J, Schechter M, Markowitz M, Loufty M, Zhao J, Isaacs R, Nguyen BY, Teppler H, Group tB-S (2007) Results of BENCHMRK-2, a phase III study evaluating the eYcacy and safety of MK-0518, a novel HIV-1 integrase inhibitor, in patients with triple-class resistant virus. In: 14th conference on retroviruses and opportunistic infections (CROI), Los Angeles, CA, USA, 25-28 February 2007. p Abstract 105bL.B.
5. Zolopa AR, Berger DS, Lampiris H, Zhong L, Chuck SL, Enejosa JV, Kearney BP, Cheng AK (2010) Activity of elvitegravir, a once-daily integrase inhibitor, against resistant HIV Type 1: Results of a phase 2, randomized, controlled, dose-ranging clinical trial. J Infect Dis 201(6):814-822. doi:10.1086/650698
6. Arribas J, Lazzarin A, RaY F, Rakhmanova A, Richmond G, Rockstroh J, van Lunzen J, Young B, Almond S, Brothers C, Min S, Nichols G (2010) Once-daily S/GSK1349572 as part of combination therapy in antiretroviral naïve adults: Rapid and potent antiviral responses in the interim 16-week analysis from SPRING-1 (ING112276). In: 18th international conference on AIDS, Vienna, Austria, 2010. p Abstract THLBB205
7. Eron J, Durant J, Poizot-Martin I, Reynes J, Soriano V, Kumar P, Richmond G, Vittecoq D, Fujiwara T, Ait-Khaled M, Min S, Thomas D, CuVe R, Yeo J (2010) Activity of a next generation integrase inhibitor (INI), S/GSK1349572, in subjects with HIV exhibiting raltegravir resistance: Initial results of VIKING study (ING112961). In: 18th international conference on AIDS, Vienna, Austria, 2010. p Abstract MOAB0105
8. DeJesus E, Berger D, Markowitz M, Cohen C, Hawkins T, Ruane P, Elion R, Farthing C, Zhong L, Cheng AK, McColl D, Kearney BP (2006) Antiviral activity, pharmacokinetics, and dose response of the HIV-1 integrase inhibitor GS-9137 (JTK-303) in treatmentnaive and treatment-experienced patients. J Acquir Immune DeWc Syndr 43(1):1-5
9. Grinsztejn B, Nguyen B, Katlama CB, Gatell J, Lazzarin A, Vittecoq D, Gonzalez C, Chen J, Isaacs R, Team TP (2007) 48 week eYcacy and safety of MK-0518, a novel HIV-1 integrase inhibitor, in patients with triple-class resistant virus. In: 47th ICAAC, Chicago, 2007. Abstract H-713
10. Hazuda DJ, Miller MD, Nguyen BY, Zhao J (2007) Resistance to HIV-integrase inhibitor raltegravir: Analysis of protocol 005, a Phase II study in patients with triple-class resistant HIV-1 infection. Antiviral Ther 12:10
11. Lennox J, DeJesus E, Lazzarin A, Pollard R, Madruga JVR, Zhao J, Xu X, Williams-Diaz A, Rodgers A, DiNubile M, Nguyen BY, Leavitt R, Sklar P, Investigators tS (2008) Safety and eYcacy of Raltegravir-based versus Efavirenz-based combination therapy in treatment naive HIV-1 infected patients. STARTMRK protocol 021. In: ICAAC-IDSA Washington DC, USA, 2008. Abstract H-896a
12. Taylor BS, Sobieszczyk ME, McCutchan FE, Hammer SM (2008) The challenge of HIV-1 subtype diversity. N Engl J Med 358(15): 1590-1602
13. Deforche K, Silander T, Camacho R, Grossman Z, Soares MA, Van Laethem K, Kantor R, Moreau Y, Vandamme AM (2006) Analysis of HIV-1 pol sequences using Bayesian networks: Implications for drug resistance. Bioinformatics 22(24):2975-2979
14. Kantor R, Katzenstein DA, Efron B, Carvalho AP, Wynhoven B, Cane P, Clarke J, Sirivichayakul S, Soares MA, Snoeck J, Pillay C, Rudich H, Rodrigues R, Holguin A, Ariyoshi K, Bouzas MB, Cahn P, Sugiura W, Soriano V, Brigido LF, Grossman Z, Morris L, Vandamme AM, Tanuri A, Phanuphak P, Weber JN, Pillay D, Harrigan PR, Camacho R, Schapiro JM, Shafer RW (2005) Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: Results of a global collaboration. PLoS Med 2(4):e112
15. Sichtig N, Sierra S, Kaiser R, Däumer MP, Reuter S, Schülter E, Altmann A, Fäktenheuer G, Dittmer U, PWster H, Esser S (2009) Raltegravir resistance mutation proWles: Baseline situation and modiWcation during treatment. J Antimicrob Chemother 64(1): 25-32
16. Stürmer M, Doerr HM, Gürtler L (2009) Human immunodeWciency virus: 25 years of diagnostic and therapeutic strategies and their impact on hepatitis B and C virus. Med Microbiol Immunol 198(3):147-155. doi:10.1007/s00430-009-0117-6
17. Fransen S, Grupta S, Danovich R, Hazuda DJ, Miller M, Witmer M, Petropoulos CJ, Parkin NT, Huang W (2008) Loss of raltegravir susceptibility in treated patients is conferred by multiple nonoverlapping genetic pathways. Antiviral Ther 13(Suppl 3):A9
18. Fransen S, Karmochkine M, Huang W, Weiss L, Petropoulos CJ, Charpentier C (2009) Longitudinal analysis of raltegravir susceptibility and integrase replication capacity of human immunodeWciency virus type 1 during virologic failure. Antimicrob Agents Chemother 53(10):4522-4524. doi:10.1128/AAC.00651-09
19. Miller MD, Danovich RM, Ke Y, Witmer M, Zhao J, Harvey CM, Nguyen BY, Hazuda DJ (2008) Longitudinal analysis of resistance to the HIV-1 integrase inhibitor reltegravir: Results from P005 a phase II study in treatment-experienced patients. Antiviral Ther 13(Suppl 3):A8
20. Anies G, da Silva D, Recordon-Pinson P, Reigadas S, Wittkop L, Neau D, Morlat P, Fleury H, Masquelier B (2009) Analysis of raltegravir- resistant patterns including mutations at positions 143 and 155 in the HIV-1 integrase. In: 16th conference on retroviruses and opportunistic infections (CROI), San Francisco, CA, USA, February 16-19, 2009. Abstract 619
21. Jones G, Ledford R, Yu F, Miller M, Tsiang M, McColl D (2007) Resistance proWle of HIV-1 mutants in vitro selected by the HIV-1 integrase inhibitor, GS-9137 (JTK-303). In: 14th conference on retroviruses and opportunistic infections (CROI), Los Angeles, CA, USA, 25-28 February 2007. Foundation for retrovirology and human health, Alexandria, VA, USA, p Abstract 627
22. Hackett Jr J, Harris B, Holzmayer V, Yamaguchi J, Luk KC, Brennan C, Schochetman G, Devare S, Swanson P (2008) Naturally occurring polymorphisms in HIV-1 group M, N, and O integrase: Implications for integrase inhibitors. In: 15th conference on retroviruses and opportunistic infections (CROI), Boston, MA, USA, 3-6 February 2008. Foundation for retrovirology and human health, Alexandria, VA, USA, p Abstract 872
23. Garrido C, Geretti AM, de Mendoza C, Booth C, Strang A, Soriano V Polymorphisms at the integrase gene in distinct HIV populations may inXuence the susceptibility to integrase inhibitors. In: 6th European HIV Drug Resistance Workshop, Budapest, Hungary, 26-28 March 2008. Virology Education, BJ Utrecht, Netherlands, p Abstract 12
24. Yerly S, Hirschel B, Gaille C, Kaiser L, Perrin L (2007) Polymorphism of HIV-1 subtypes B and non-B integrase gene. In: 14th conference on retroviruses and opportunistic infections (CROI), Los Angeles, CA, USA, 25-28 February 2007. Foundation for retrovirology and human health, Alexandria, VA, USA, p Abstract 626
25. Lataillade M, Chiarella J, Kozal MJ (2007) Natural polymorphism of the HIV-1 integrase gene and mutations associated with integrase inhibitor resistance. Antivir Ther 12(4):563-570
26. Myers RE, Pillay D (2007) HIV-1 integrase sequence variation and covariation. Antiviral Ther 12:5
27. Van Baelen K, Rondelez E, Van Eygen V, Smits V, Van den Zegel P, Stuyver LJ (2008) Validation of a genotypic and phenotypic recombinant viruses assay to determine resistance against HIV-1 inhibitors Antiviral Ther 13(Suppl 3 A127
28. Goodman D, Hluhanich R, Waters J, Margot NA, Fransen S, Gupta S, Huang W, Parkin N, Borroto-Esoda K, Svarovskaia ES, Miller MD, McColl DJ (2008) Integrase inhibitor resistance involves complex interactions among primary and secondary resistance mutations: A novel mutation L68 V/I associates with E92Q and increases resistance. In: XVII international HIV drug resistance workshop sitges, Spain, 2008. p Abstract 7
29. Van Baelen K, Van Eygen V, Rondelez E, Stuyver LJ (2008) Clade-speciWc HIV-1 integrase polymorphisms do not reduce raltegravir and elvitegravir phenotypic susceptibility. AIDS 22(14): 1877-1880. doi:10.1097/QAD. 0b013e32830f9703
30. Hu Z, Kuritzkes DR (2010) EVect of raltegravir resistance mutations in HIV-1 integrase on viral Wtness. J Acquir Immune DeWc Syndr 55(2):148-155. doi:10.1097/QAI.0b013e3181e9a87a
31. Ceccherini-Silberstein F, Armenia D, D'Arrigo R, Micheli V, Fabeni L, Meraviglia P, Capetti A, Zaccarelli M, Trotta MP, Narciso P, Antinori A, Perno CF (2008) Virological response and resistance in multi-experienced patients treated with raltegravir. Antiviral ther 13(Suppl 3):A15
32. Brenner BG, Lowe M, Moisi D, Hardy I, Gagnon S, Charest H, Baril JG, Wainberg MA, Roger M (2011) Subtype diversity associated with the development of HIV-1 resistance to integrase inhibitors. J Med Virol
33. da Silva D, Van Wesenbeeck L, Breilh D, Reigadas S, Anies G, Van Baelen K, Morlat P, Neau D, Dupon M, Wittkop L, Fleury H, Masquelier B (2010) HIV-1 resistance patterns to integrase inhibitors in antiretroviral-experienced patients with virological failure on raltegravir-containing regimens. J Antimicrob Chemother 65(6):1262-1269